目的 观察馥感啉口服液治疗小儿急性上呼吸道感染在广泛应用条件下的有效性和安全性。方法 采用多中心、观察性研究的方法，收集2 124例急性上呼吸道感染的患儿，服用馥感啉口服液，疗程为1周。分别从不同剂量、年龄段、辨证/辨病以及治疗手段方面，观察各组的痊愈率、继发下呼吸道感染/呼吸道并发症的情况，并对其安全性进行评价。结果 馥感啉口服液治疗感冒总痊愈率为95.12%；倍增剂量与标准剂量、辨证（气虚风热证、风热证）与辨病的痊愈率比较，差异无统计学意义；不同年龄段和不同治疗方式的痊愈率比较，差异有统计学意义，其中以<1岁年龄段患者及单独服用馥感啉的患者痊愈率较高。并发症总发生率为0.24%；倍增剂量与标准剂量、不同年龄段、辨证（气虚风热证、风热证）与辨病的并发症发生率比较，差异均无统计学意义；单独用药的并发症发生率低于联合用药。整体总临床不良事件及不良反应发生率分别为1.37%、1.04%。；临床不良事件及不良反应发生率比较，除不同剂量组外，差异均有统计学意义。结论 馥感啉口服液治疗小儿急性上呼吸道感染具有较高的临床痊愈率和较低的并发症发生率，疗效较好；对于气虚风热证、风热证，甚至辨病治疗，有着较好而接近的疗效；年龄越小治疗痊愈率稍高。临床不良事件/不良反应的总发生率较低，倍增剂量未显示出较标准剂量更高的安全风险。提示该品种有着较好的临床应用前景。

Objective To evaluate the clinical efficacy and safety of Fuganlin Oral Liquid in treatment of acute upper respiatory infection (AURI) in pratical application. Methods A multi-centered observational study was conducted. Total 2124 patients were administrated with Fuganlin Oral Liquid for one week, and observed the cure rate and the occurrence rate of complications in different levels, and the safety was evaluated. Results The total cure rate was 95.12%, and there was no significant difference on it among different dosage and diagnosis groups, while patients (younger than one year old) took Fuganlin Oral Liquid alone had higher cure rate. The occurrence rate of complications was 0.24%, and there was no statistical difference among different dosage, age, and diagnosis groups, while patient took Fuganlin Oral Liquid alone had lower rate than combination therapy. The rateS of adverse events and adverse reaction were 1.37% and 1.04%, there was statistical difference except in different dosage groups. Conclusion Fuganlin Oral Liquid has high cure rate and low complication rate. It has a good clinical efficacy, especially in young age groups. The efficacy of Qi deficiency group and wind heat syndrome group, even the disease diagnosis group was similar. A few clinical adverse events and adverse reaction was founded, high dosage group was as safe as the low dosage group. Above all, Fuganlin Oral Liquid has widely applied prospect in clinical practice.